CRIS Current Research Information System

MANCUSO, KATIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.655
NA - Nord America 2.733
EU - Europa 2.015
AF - Africa 244
SA - Sud America 234
OC - Oceania 2
Totale 8.883
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.683
CN - Cina 1.124
SG - Singapore 987
VN - Vietnam 805
IT - Italia 628
GB - Regno Unito 304
DE - Germania 237
HK - Hong Kong 235
KR - Corea 220
SE - Svezia 206
BR - Brasile 179
IN - India 153
NL - Olanda 152
CI - Costa d'Avorio 118
RU - Federazione Russa 88
FR - Francia 73
IE - Irlanda 71
FI - Finlandia 54
SC - Seychelles 46
JP - Giappone 42
TG - Togo 34
UA - Ucraina 34
ZA - Sudafrica 30
BG - Bulgaria 29
BE - Belgio 26
AR - Argentina 25
AT - Austria 25
CA - Canada 24
MX - Messico 22
EE - Estonia 20
ID - Indonesia 17
CH - Svizzera 16
ES - Italia 16
JO - Giordania 15
PL - Polonia 14
BD - Bangladesh 12
NG - Nigeria 9
CO - Colombia 8
EC - Ecuador 7
PH - Filippine 7
TR - Turchia 6
CZ - Repubblica Ceca 5
IR - Iran 5
CL - Cile 4
IQ - Iraq 3
LT - Lituania 3
PE - Perù 3
PK - Pakistan 3
PY - Paraguay 3
RO - Romania 3
RS - Serbia 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
CY - Cipro 2
DO - Repubblica Dominicana 2
GH - Ghana 2
KZ - Kazakistan 2
LB - Libano 2
LV - Lettonia 2
SA - Arabia Saudita 2
UY - Uruguay 2
AO - Angola 1
AU - Australia 1
DZ - Algeria 1
GE - Georgia 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MA - Marocco 1
MN - Mongolia 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
QA - Qatar 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TN - Tunisia 1
TW - Taiwan 1
VE - Venezuela 1
ZM - Zambia 1
Totale 8.883
Salva come PNG Salva come JPEG
Città #
Singapore 669
Hefei 472
Ashburn 398
Chandler 275
Southend 236
Hong Kong 235
Ho Chi Minh City 231
Seoul 219
Dallas 199
Fairfield 199
Bologna 180
Hanoi 169
Abidjan 118
Ann Arbor 115
Beijing 110
Woodbridge 107
Seattle 93
Wilmington 86
Houston 81
Santa Clara 71
Dublin 67
Los Angeles 66
Cambridge 63
Boardman 60
Princeton 58
Dong Ket 57
New York 48
Milan 47
Bengaluru 46
Tokyo 40
Hyderabad 38
Munich 36
Lomé 34
Haiphong 31
Helsinki 30
Buffalo 28
Sofia 28
Bremen 27
Turin 27
Frankfurt am Main 26
Brussels 24
São Paulo 23
Fabriano 22
Westminster 22
Florence 21
Berlin 20
Jinan 20
Padova 20
Redondo Beach 20
Dongguan 18
Nanjing 18
Redmond 18
Nuremberg 17
Vienna 17
Rome 16
Amman 15
Amsterdam 15
Lappeenranta 15
Tongling 14
Changsha 13
Guangzhou 13
Ha Long 13
Ninh Bình 13
Quận Bình Thạnh 13
San Diego 13
Tianjin 13
Jacksonville 12
London 12
Shenzhen 12
Atlanta 11
Bern 11
Biên Hòa 11
Brooklyn 11
Jakarta 11
Falkenstein 10
Falls Church 10
Redwood City 10
Shenyang 10
Thái Nguyên 10
Abeokuta 9
Mexico City 9
Quận Một 9
Saint Petersburg 9
Turku 9
Warsaw 9
Yubileyny 9
Zhengzhou 9
Chicago 8
Nanchang 8
Paris 8
San Francisco 8
Shanghai 8
Stockholm 8
Toronto 8
Bắc Ninh 7
Can Tho 7
Council Bluffs 7
Da Nang 7
Fuzhou 7
Genoa 7
Totale 5.877
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 663
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 274
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 236
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 230
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 229
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 206
A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role? 188
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 181
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 179
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 175
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 173
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 171
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 171
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 168
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 164
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 160
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 159
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 159
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 153
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 152
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 150
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 150
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 149
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 149
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 148
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 145
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 143
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 141
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 135
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 131
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 128
Role of consolidation therapy in transplant eligible multiple myeloma patients. 127
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma 126
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 125
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 122
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 120
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 117
Multidisciplinary Management of Sternal Osteomyelitis Due to Klebsiella aerogenes after Open Heart Surgery in a Patient with Multiple Myeloma: A Case Report and Discussion of the Literature 116
Pomalidomide combinations are a safe and effective option after daratumumab failure 115
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 115
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 110
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 110
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 108
A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents 107
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 107
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients 100
null 98
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 97
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 96
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 95
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients 94
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 88
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma 82
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 80
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 74
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study 74
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 74
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 72
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight 68
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 66
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 63
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 60
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 50
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS 37
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing 35
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 35
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study 31
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 29
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma 26
VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation 24
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 24
Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy 20
Correction: Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma 20
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients 14
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial 14
Totale 9.125
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.824
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.824
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021307 0 0 0 0 0 26 14 29 52 22 26 138
2021/2022748 70 38 42 70 58 23 18 53 29 92 126 129
2022/20231.010 83 140 36 151 74 96 27 56 164 28 98 57
2023/2024455 29 40 25 36 26 91 16 91 11 35 37 18
2024/20251.867 110 167 153 135 127 66 133 64 55 222 214 421
2025/20263.622 575 1.130 569 578 507 263 0 0 0 0 0 0
Totale 9.125